Literature DB >> 18810690

Diagnosis and treatment of infections due to Mycobacterium avium complex.

Shannon H Kasperbauer1, Charles L Daley.   

Abstract

MYCOBACTERIUM AVIUM complex (MAC) consists of nontuberculous mycobacteria that cause disease in immunocompromised and immunocompetent hosts. The organisms are ubiquitous in the environment, and acquisition occurs through ingestion or inhalation of aerosols from soil, water, or biofilms. Disease may manifest as disseminated infection, soft tissue infection, chronic pneumonia, or hypersensitivity pneumonitis. Nontuberculous mycobacteria are increasingly associated with pulmonary disease, with MAC being the most common nontuberculous mycobacteria to cause pulmonary disease in the United States. Pulmonary symptoms, nodular or cavitary opacities on a chest radiograph or high-resolution computed tomographic scan with multifocal bronchiectasis and multiple small nodules, plus positive culture results from two sputum specimens or one bronchoscopic specimen are consistent with MAC pulmonary disease. Treatment consists of a macrolide, rifamycin, and ethambutol given three times weekly for noncavitary disease and daily with or without an aminoglycoside for cavitary disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810690     DOI: 10.1055/s-0028-1085708

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  20 in total

Review 1.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

2.  Identification of mycobacteria from solid and liquid media by matrix-assisted laser desorption ionization-time of flight mass spectrometry in the clinical laboratory.

Authors:  J M Balada-Llasat; Kamal Kamboj; Preeti Pancholi
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  IL-32 expression in the airway epithelial cells of patients with Mycobacterium avium complex lung disease.

Authors:  Xiyuan Bai; Alida R Ovrutsky; Marinka Kartalija; Kathryn Chmura; Amanda Kamali; Jennifer R Honda; Rebecca E Oberley-Deegan; Charles A Dinarello; James D Crapo; Ling-Yi Chang; Edward D Chan
Journal:  Int Immunol       Date:  2011-10-27       Impact factor: 4.823

5.  Correlation between variable-number tandem-repeat-based genotypes and drug susceptibility in Mycobacterium avium isolates.

Authors:  Y Tatano; C Sano; K Yasumoto; T Shimizu; K Sato; K Nishimori; T Matsumoto; S Yano; H Takeyama; H Tomioka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-12       Impact factor: 3.267

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients.

Authors:  Pedro Henrique Campanini Cândido; Luciana de Souza Nunes; Elizabeth Andrade Marques; Tânia Wrobel Folescu; Fábrice Santana Coelho; Vinicius Calado Nogueira de Moura; Marlei Gomes da Silva; Karen Machado Gomes; Maria Cristina da Silva Lourenço; Fábio Silva Aguiar; Fernanda Chitolina; Derek T Armstrong; Sylvia Cardoso Leão; Felipe Piedade Gonçalves Neves; Fernanda Carvalho de Queiroz Mello; Rafael Silva Duarte
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

8.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

9.  Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

Authors:  Kenneth N Olivier; Pamela A Shaw; Tanya S Glaser; Darshana Bhattacharyya; Michelle Fleshner; Carmen C Brewer; Christopher K Zalewski; Les R Folio; Jenifer R Siegelman; Shamira Shallom; In Kwon Park; Elizabeth P Sampaio; Adrian M Zelazny; Steven M Holland; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2014-01

10.  Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease.

Authors:  Yun Su Sim; Hye Yun Park; Kyeongman Jeon; Gee Young Suh; O Jung Kwon; Won-Jung Koh
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.